574625 Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem

574625
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₅₁H₃₄N₆O₂₃S₆ . 6Na 129-46-4

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
574625-50MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 50 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of Gα-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids.
      Catalogue Number574625
      Brand Family Calbiochem®
      SynonymsPTP Inhibitor VI, P2Y Antagonist I, Purinergic Receptor P2Y Antagonist I
      References
      ReferencesMeyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
      Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
      Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
      Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
      Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
      Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
      Denhertog, A., et al. 1992. J. Physiol. 454, 591.
      Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
      Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
      Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
      Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.
      Product Information
      CAS number129-46-4
      ATP CompetitiveN
      FormWhite crystalline solid
      Hill FormulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
      Chemical formulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetprotein tyrosine phosphatases
      Primary Target IC<sub>50</sub>15 µM against phospholipase D
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSQM7000000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem Certificates of Analysis

      TitleLot Number
      574625

      References

      Reference overview
      Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
      Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
      Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
      Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
      Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
      Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
      Denhertog, A., et al. 1992. J. Physiol. 454, 591.
      Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
      Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
      Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
      Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-May-2008 RFH
      SynonymsPTP Inhibitor VI, P2Y Antagonist I, Purinergic Receptor P2Y Antagonist I
      DescriptionAn anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids.
      FormWhite crystalline solid
      CAS number129-46-4
      RTECSQM7000000
      Chemical formulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (5 mg/ml)
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Toxicity Standard Handling
      Merck USA index14, 9006
      ReferencesMeyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
      Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
      Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
      Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
      Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
      Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
      Denhertog, A., et al. 1992. J. Physiol. 454, 591.
      Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
      Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
      Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
      Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.